Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance COVID-19 status Phase of research  How it helps Latest publication
1212C2
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/24/2021
Rac5c
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/04/2021
C1632
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/22/2021
CIGB-325
Potential treatment - clinical evidence Experimental Antiviral Dec/11/2020
11-(1,3-Benzodioxol-5-yl)-5-bromo-8,9-dihydro-[1,3]benzodioxolo[7,6-g]phthalazine-7,10-dione
Potential treatment - theoretical effect Experimental Antiviral Feb/22/2021
(4Ar,5R,6aS,6aR,6bR,8aS,11R,14aR,14bR)-5-hydroxy-11-(hydroxymethyl)-4,4,6a,6b,8a,11,14b-heptamethyl-2,4a,5,6,6a,7,8,9,10,13,14,14a-dodecahydro-1H-picen-3-one
Potential treatment - theoretical effect Experimental Antiviral Feb/22/2021
5-(3,4-Dimethoxyphenyl)-2-methyl-7-(5,6,7,8-tetrahydronaphthalen-2-yl)-5,7-dihydro-[1,3]thiazolo[3,2-a]pyrimidine-3,6-dione
Potential treatment - theoretical effect Experimental Antiviral Feb/22/2021
Genz-667161
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/24/2021
Genz-123346
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/24/2021
Infliximab
Potential treatment - clinical evidence Experimental Antiviral Feb/01/2021
(S)-3-((S)-3-(4-methoxyphenyl)-2-((S)-2-(2-morpholinoacetamido)propanamido) propanamido)-2-oxo-N,4-diphenylbutanamide
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/10/2021
mAb 2-7
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/08/2021
Imiglitazar
Potential treatment - theoretical effect Experimental Antiviral Feb/23/2021
rSIFN-co
Potential treatment - clinical evidence Experimental Antiviral Feb/23/2021
VHH WE
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/12/2021
aRBD-2-7
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/03/2021
VHH EW
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/12/2021
ΔCS-PP
Potential treatment - pre-clinical evidence Experimental Vaccine Mar/02/2021
MLN-4760
Potential treatment - theoretical effect Experimental Antiviral Mar/03/2021
hACE221-55A36K-F40E
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/02/2021